Search research articles
Contact Us
Filters
Showing results (121-130 of 182) with videos related to
Page
of 19
Sort By:
The European Respiratory Journal
|
September 26, 2024
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies
Michael E Wechsler, Guy Brusselle, J Christian Virchow, et al.
The European Respiratory Journal
|
June 20, 2024
Clinical remission with biologic therapies in severe asthma: a matter of definition
, P Jane McDowell, Ron McDowell, et al.
The European Respiratory Journal
|
October 19, 2023
Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry
P Jane McDowell, Ron McDowell, John Busby, et al.
The Lancet. Respiratory Medicine
|
February 15, 2026
Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials
Alberto Papi, Robert A Wise, David J Jackson, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
July 20, 2024
Clinical and Economic Burden of Severe Asthma With Low Blood Eosinophil Counts
John Busby, Shruti Menon, Neil Martin, et al.
The New England Journal of Medicine
|
September 9, 2024
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
David J Jackson, Michael E Wechsler, Daniel J Jackson, et al.
Mayo Clinic Proceedings
|
September 20, 2021
Eosinophils in Health and Disease: A State-of-the-Art Review
Michael E Wechsler, Ariel Munitz, Steven J Ackerman, et al.
The Lancet. Respiratory Medicine
|
October 7, 2021
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study
Andrew Menzies-Gow, Mark Gurnell, Liam G Heaney, et al.
Mucosal Immunology
|
July 28, 2023
IL-33-induced neutrophilic inflammation and NETosis underlie rhinovirus-triggered exacerbations of asthma
Bodie Curren, Tufael Ahmed, Daniel R Howard, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
April 10, 2022
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose
Christian Domingo, Jorge F Maspero, Mario Castro, et al.
Page
of 19
Search research articles
Search
Showing results (121-130 of 182) with videos related to
Sort By:
Page
of 19
The European Respiratory Journal
|
September 26, 2024
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies
Michael E Wechsler, Guy Brusselle, J Christian Virchow, et al.
The European Respiratory Journal
|
June 20, 2024
Clinical remission with biologic therapies in severe asthma: a matter of definition
, P Jane McDowell, Ron McDowell, et al.
The European Respiratory Journal
|
October 19, 2023
Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry
P Jane McDowell, Ron McDowell, John Busby, et al.
The Lancet. Respiratory Medicine
|
February 15, 2026
Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials
Alberto Papi, Robert A Wise, David J Jackson, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
July 20, 2024
Clinical and Economic Burden of Severe Asthma With Low Blood Eosinophil Counts
John Busby, Shruti Menon, Neil Martin, et al.
The New England Journal of Medicine
|
September 9, 2024
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
David J Jackson, Michael E Wechsler, Daniel J Jackson, et al.
Mayo Clinic Proceedings
|
September 20, 2021
Eosinophils in Health and Disease: A State-of-the-Art Review
Michael E Wechsler, Ariel Munitz, Steven J Ackerman, et al.
The Lancet. Respiratory Medicine
|
October 7, 2021
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study
Andrew Menzies-Gow, Mark Gurnell, Liam G Heaney, et al.
Mucosal Immunology
|
July 28, 2023
IL-33-induced neutrophilic inflammation and NETosis underlie rhinovirus-triggered exacerbations of asthma
Bodie Curren, Tufael Ahmed, Daniel R Howard, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
April 10, 2022
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose
Christian Domingo, Jorge F Maspero, Mario Castro, et al.
Page
of 19